<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643431</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #20D.699</org_study_id>
    <nct_id>NCT04643431</nct_id>
  </id_info>
  <brief_title>Risk Assessment of Carotid Plaques Using 3D Contrast-Enhanced Ultrasound</brief_title>
  <official_title>Risk Assessment of Carotid Plaques Based on Pressure Estimation Using 3D Contrast-enhanced Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized study conducted at Thomas Jefferson University&#xD;
      comparing pressure-gradient estimates (obtained between a carotid plaque and the carotid&#xD;
      artery) to imaging and histology markers of plaque vulnerability. There is an inverse&#xD;
      relationship between the subharmonic signal magnitude from contrast-enhanced ultrasound&#xD;
      microbubbles and ambient pressure. This pressure estimation technique (referred as SHAPE)&#xD;
      will be used to estimate the pressure gradient across the carotid plaque cap noninvasively in&#xD;
      vivo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the pressure gradient and surrogate (imaging and histological) predictors</measure>
    <time_frame>pre-endarterectomy</time_frame>
    <description>The estimates of pressure-gradient across the plaque cap from 3D SHAPE technique will be compared with the surrogate imaging and histological predictors using Pearson's correlation coefficient. The correlations between the surrogate predictors will be also calculated using Pearson's correlation coefficient. We expect the pressure-gradient estimates from SHAPE technique is moderately correlated (above 0.5) with the surrogate predictors.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Carotid SHAPE estimation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ultrasound contrast agent is infused (4-10 mL/min). An area within the plaque demonstrating internal flow is selected and a software based calibration algorithm is executed. After selecting the optimal acoustic output power 3D SHAPE volumes of the entire plaque (including the carotid artery) are acquired. Infusion is stopped and after microbubble clearance a second set of 3D SHAPE volumes (without contrast) are obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Perflutren</intervention_name>
    <description>The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.</description>
    <arm_group_label>Carotid SHAPE estimation</arm_group_label>
    <other_name>SHAPE with Definity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years old and willing and able to participate. Patients with&#xD;
             atherosclerosis scheduled for carotid endarterectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Pregnancy or breast-feeding at the time of the scan&#xD;
&#xD;
               -  Patients with known hypersensitivity or allergy to any component (including&#xD;
                  perflutren) of Definity (Lantheus Medical Imaging, Billerica, MA).&#xD;
&#xD;
               -  Patients who are medically unstable, patients who are seriously or terminally&#xD;
                  ill, and patients whose clinical course is unpredictable. For example:&#xD;
&#xD;
                    -  Patients on life support or in a critical care unit.&#xD;
&#xD;
                    -  Patients with unstable occlusive disease (e.g., crescendo angina).&#xD;
&#xD;
                    -  Patients with clinically unstable cardiac arrhythmias, such as recurrent&#xD;
                       ventricular tachycardia.&#xD;
&#xD;
                    -  Patients with uncontrolled congestive heart failure (NYHA Class IV).&#xD;
&#xD;
                    -  Patients with recent cerebral hemorrhage.&#xD;
&#xD;
                    -  Patients who have undergone surgery within 24 hours prior to the study&#xD;
                       sonographic examination.&#xD;
&#xD;
               -  Patients with unstable cardiopulmonary conditions (acute myocardial infarction,&#xD;
                  acute coronary artery syndromes, worsening or unstable congestive heart failure,&#xD;
                  or serious ventricular arrhythmias) or respiratory distress syndrome.&#xD;
&#xD;
               -  Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary&#xD;
                  hypertension or a history of pulmonary emboli.&#xD;
&#xD;
               -  Patients who have received any contrast medium (X-ray, MRI, CT or ultrasound) in&#xD;
                  the 24 hours prior to the research ultrasound exam&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kibo Nam, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Zaccagnini</last_name>
    <phone>215-955-8133</phone>
    <email>Diana.Zaccagnini@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Zaccagnini</last_name>
      <phone>215-955-8133</phone>
      <email>diana.zaccagnini@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

